Mifepristone is a new anti-progestogen drug, which has no progestogen, estrogen, androgen and anti-estrogen activity. It can bind to progesterone receptor and glucocorticoid receptor, and its affinity to endometrial progesterone receptor is 5 times stronger than progesterone. Mifepristone can induce delivery at all stages of pregnancy in pregnant animals and can be used as a non-surgical anti-early pregnancy drug. The effective dose has no obvious effect on cortisol level. Because drugs can't induce enough uterine activity, when they are only used to prevent early pregnancy, the rate of incomplete abortion is higher, but it can increase the sensitivity of uterus to prostaglandin.

Model medical papers on mifepristone application, please see: Innovative Medical Network.

The following are all medical papers of Innovative Medical Network.

Clinical application progress of mifepristone in obstetrics and gynecology

Clinical analysis of mifepristone combined with rivanol in termination of second trimester pregnancy

Clinical observation of mifepristone and methyltestosterone in the treatment of abnormal bleeding in perimenopausal period

Application of mifepristone combined with methotrexate in the treatment of ectopic pregnancy

Analysis of related factors of successful abortion of mifepristone combined with misoprostol

Clinical observation of mifepristone in the treatment of perimenopausal hysteromyoma

Mifepristone combined with methotrexate in the treatment of 30 cases of ectopic pregnancy